ATE227118T1 - Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus - Google Patents
Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virusInfo
- Publication number
- ATE227118T1 ATE227118T1 AT94925160T AT94925160T ATE227118T1 AT E227118 T1 ATE227118 T1 AT E227118T1 AT 94925160 T AT94925160 T AT 94925160T AT 94925160 T AT94925160 T AT 94925160T AT E227118 T1 ATE227118 T1 AT E227118T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- virus
- cytotoxic
- against hepatitis
- induring
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108700024845 Hepatitis B virus P Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10087093A | 1993-08-02 | 1993-08-02 | |
| PCT/US1994/008685 WO1995003777A1 (en) | 1993-08-02 | 1994-08-01 | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE227118T1 true ATE227118T1 (de) | 2002-11-15 |
Family
ID=22281958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94925160T ATE227118T1 (de) | 1993-08-02 | 1994-08-01 | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0726758B1 (de) |
| JP (2) | JP3650110B2 (de) |
| AT (1) | ATE227118T1 (de) |
| AU (1) | AU702367B2 (de) |
| CA (1) | CA2168583C (de) |
| DE (1) | DE69431665T2 (de) |
| DK (1) | DK0726758T3 (de) |
| ES (1) | ES2187530T3 (de) |
| NZ (1) | NZ271531A (de) |
| PT (1) | PT726758E (de) |
| WO (1) | WO1995003777A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607727B1 (en) | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
| US6689363B1 (en) | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| US6235288B1 (en) | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| US5858689A (en) * | 1993-07-22 | 1999-01-12 | Ludwig Institute For Cancer Research | Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof |
| EP0914142B9 (de) * | 1996-03-11 | 2012-01-04 | Epimmune Inc. | Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle |
| DE69820486D1 (de) * | 1998-01-19 | 2004-01-22 | Mogam Biotechnology Res Inst Y | Liposomen, enthaltend peptidantigene, welche vom x-protein aus hepatitis b virus abstammen |
| CA2370413A1 (en) * | 1999-06-29 | 2001-01-04 | Epimmune Inc. | Hla binding peptides and their uses |
| WO2002020616A1 (en) * | 2000-09-01 | 2002-03-14 | Epimmune Inc. | Hla-a2.1 binding peptides and their uses |
| KR20100056507A (ko) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드 ｐｒｏ－ｇｌｙ－ｔｈｒ－ｃｙｓ－ｇｌｕ－ｉｌｅ－ｃｙｓ－ａｌａ－ｔｙｒ－ａｌａ－ａｌａ－ｃｙｓ－ｔｈｒ－ｇｌｙ－ｃｙｓ의 용도 |
| EP2391635B1 (de) | 2009-01-28 | 2017-04-26 | Epimmune Inc. | Pan-dr-bindende polypeptide und verwendungen davon |
| TWI575070B (zh) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| CA2950863C (en) * | 2014-06-02 | 2023-01-17 | Isa Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
| EP3443107A1 (de) | 2016-04-13 | 2019-02-20 | Synthetic Genomics, Inc. | Rekombinante arterivirus-replikon-systeme und verwendungen davon |
| SG11201811442UA (en) | 2016-06-20 | 2019-01-30 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
| WO2018075235A1 (en) | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
| EP3548625B1 (de) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur erhöhung der genexpression |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
| KR20200101416A (ko) * | 2017-12-19 | 2020-08-27 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv) 백신 및 그 용도 |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| CN111902163B (zh) | 2018-01-19 | 2024-02-13 | 杨森制药公司 | 使用重组复制子系统诱导和增强免疫应答 |
| KR102234027B1 (ko) * | 2018-05-09 | 2021-03-31 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드 및 이의 항바이러스 용도 |
| JP2024527098A (ja) * | 2021-07-30 | 2024-07-19 | テヴォジェン バイオ インコーポレイテッド | 以前の免疫から逃れるように進化する変異体を含むウイルス感染症を治療するための複数のウイルスエピトープに対するｃｄ３＋ｃｄ８＋細胞を開発するための方法 |
| CN118580322A (zh) * | 2022-01-05 | 2024-09-03 | 成都朗谷生物科技股份有限公司 | 针对乙型肝炎病毒的抗原肽 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102963A0 (en) * | 1991-08-26 | 1993-01-31 | Scripps Research Inst | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
| IL106610A0 (en) * | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
| NZ263050A (en) * | 1993-03-05 | 1997-11-24 | Cytel Corp | Compositions of immunogenic peptides with hla-a2.1 binding motifs |
-
1994
- 1994-08-01 JP JP50605395A patent/JP3650110B2/ja not_active Expired - Fee Related
- 1994-08-01 AU AU75184/94A patent/AU702367B2/en not_active Ceased
- 1994-08-01 PT PT94925160T patent/PT726758E/pt unknown
- 1994-08-01 WO PCT/US1994/008685 patent/WO1995003777A1/en active IP Right Grant
- 1994-08-01 EP EP94925160A patent/EP0726758B1/de not_active Expired - Lifetime
- 1994-08-01 ES ES94925160T patent/ES2187530T3/es not_active Expired - Lifetime
- 1994-08-01 CA CA002168583A patent/CA2168583C/en not_active Expired - Fee Related
- 1994-08-01 NZ NZ271531A patent/NZ271531A/en not_active IP Right Cessation
- 1994-08-01 AT AT94925160T patent/ATE227118T1/de active
- 1994-08-01 DK DK94925160T patent/DK0726758T3/da active
- 1994-08-01 DE DE69431665T patent/DE69431665T2/de not_active Expired - Lifetime
-
2004
- 2004-09-30 JP JP2004287144A patent/JP2005170926A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK0726758T3 (da) | 2003-03-03 |
| JPH09501165A (ja) | 1997-02-04 |
| PT726758E (pt) | 2003-03-31 |
| ES2187530T3 (es) | 2003-06-16 |
| JP3650110B2 (ja) | 2005-05-18 |
| EP0726758B1 (de) | 2002-11-06 |
| JP2005170926A (ja) | 2005-06-30 |
| WO1995003777A1 (en) | 1995-02-09 |
| EP0726758A1 (de) | 1996-08-21 |
| AU7518494A (en) | 1995-02-28 |
| AU702367B2 (en) | 1999-02-18 |
| DE69431665T2 (de) | 2003-08-21 |
| DE69431665D1 (de) | 2002-12-12 |
| NZ271531A (en) | 1998-02-26 |
| CA2168583C (en) | 2007-10-02 |
| EP0726758A4 (de) | 1997-01-29 |
| CA2168583A1 (en) | 1995-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE227118T1 (de) | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus | |
| ATE359089T1 (de) | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus | |
| ATE320444T1 (de) | Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren | |
| PT83434B (pt) | Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida | |
| PT725824E (pt) | Epitopos de celulas t humanas imunodominantes do virus da hepatite c | |
| FR2632863B2 (fr) | Virus du fowlpox recombinant et vaccins derives de ces virus | |
| GB2255093A (en) | Hiv-1 core protein fragments | |
| PL297849A1 (en) | Vaccine against and method of treating the patients infectedwith hiv virus | |
| FR2669346B1 (fr) | Vaccin a poxvirus recombinant contre le virus de la rougeole. | |
| CA2156416A1 (en) | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus | |
| ES2162862T3 (es) | Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon. | |
| DE69433057D1 (de) | Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus | |
| HUP0003511A2 (hu) | Hepatitisz-B-vírus polipeptidek | |
| KR900016262A (ko) | 포유류 중의 HIV-억제 항체 유도성 사람 면역 결핍 바이러스(HIV) env-암호화된 펩타이드 | |
| ATE145335T1 (de) | Kreuzreaktive immunisierung gegen influenza | |
| AU627540B2 (en) | Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof | |
| SE9600436D0 (sv) | Vaccine against hantavirus | |
| MC2306A1 (fr) | Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation | |
| RU94032103A (ru) | Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации | |
| NO891355D0 (no) | Vaksinasjon mot rabis-beslektede virus. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0726758 Country of ref document: EP |